Teva and Celltrion debut Truxima, first Rituxan biosimilar, in USA

7 November 2019

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) and South Korea’s Celltrion Healthcare (Kosdaq: 068270) have today launched their Truxima (rituximab-abbs) injection, which is the first biosimilar to the reference product. Roche’s (ROG: SIX) Rituxan (rituximab) to become available in the USA with a full oncology label. The drug will be available from November 11,

Shares of Teva, which also announced financial results today, were up nearly 6% at 3,132 shekels by close of trading in Tel Aviv, while Celltrion closed down 2.8% at 191,000 won.

Truxima, which was first granted US Food and Drug Administration approval in November last year, is currently indicated for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK